A novel ErbB2 epitope targeted by human antitumor immunoagents (pages 1156–1166)
Fulvia Troise, Maria Monti, Antonello Merlino, Flora Cozzolino, Carmine Fedele, Irene Russo Krauss, Filomena Sica, Piero Pucci, Giuseppe D’Alessio and Claudia De Lorenzo
Version of Record online: 1 MAR 2011 | DOI: 10.1111/j.1742-4658.2011.08041.x
Erbicin derived immunoagents (EDIAs) are novel human, antitumor immunoconjugates selectively cytotoxic for ErbB2-positive cancer cells. Interestingly, EDIA are non-cardiotoxic and active on some Herceptin-resistant tumors. We report that EDIA bind to an epitope in the extracellular domain I of ErbB2, different from that recognised by Herceptin and other human/humanized anti-ErbB2 antibodies, which could be used as a novel therapeutic target.